Sun Pharma gets USFDA nod to market generic Cymbalta
Drug major Sun Pharma today said it has gotten the green signal from the US health regulator to market a generic version of 'Cymbalta', a capsule used for treatment of anxiety and depression, in the American market.
The company's subsidiary has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for generic duloxetine hydrochloride capsules in strengths of 20mg, 30 mg and 60 mg, Sun Pharmaceutical Industries said in a statement.
The generic duloxetine hydrochloride capsules are used for the treatment of major depressive disorder, generalised anxiety disorder and diabetic peripheral neuropathic pain, it said.
Annual sales of Cymbalta capsules amount to nearly $3 billion in the US, it added.
Shares of Sun Pharma today closed at Rs 2,272.15 on the Bombay Stock Exchange, up 0.11 per cent from the previous close.